MedMira Reports Third Quarter Results FY2024

MedMira Inc. has announced its financial results for the quarter ended April 30, 2024. The company successfully launched its US FDA approved Reveal® G4 Rapid HIV 1/2 antibody test and expanded its distribution network in the USA and Canada. MedMira also partnered with new distributors, such as Thomas Scientific, enhancing market access.

The company secured funding for clinical trials in Canada. The ReachNexus award will support MedMira's Health Canada approval for its unique Complete Syphilis (Tp/nTP) test. An official announcement is expected post-July 17, 2024, from the funding agency.

MedMira's Q3 FY2024 revenue was $81,548, compared to $148,696 in Q2 FY2024 and $106,010 in Q3 FY2023. The company reported a net loss of $603,093, a slight improvement from the $632,416 loss in the same period last year. Assets increased by $1,899,329, mainly due to investor cash, while liabilities grew by $2,679,476.

For detailed financials and management discussions, MedMira's reports are available on SEDAR.